Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03).

M, Gnant; AC, Dueck; S, Frantal; M, Martin; HJ, Burstein; R, Greil; P, Fox; AC, Wolff; A, Chan; EP, Winer; G, Pfeiler; KD, Miller; M, Colleoni; JM, Suga; G, Rubovsky; JM, Bliss; IA, Mayer; CF, Singer; Z, Nowecki; O, Hahn; J, Thomson; N, Wolmark; K, Amillano; HS, Rugo; GG, Steger; Fernández de Aránguiz B, Hernando; TC, Haddad; A, Perelló; M, Bellet; H, Fohler; Filho O, Metzger; A, Jallitsch-Halper; K, Solomon; C, Schurmans; KP, Theall; DR, Lu; K, Tenner; C, Fesl; A, DeMichele; EL, Mayer

doi:10.1200/jco.21.02554

Public

Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03).

Shared by NobleBlocks on Dec 7, 2021 • 12:00 AM UTC

Authors:

Gnant M

Dueck AC

Frantal S

Abstract

Purpose Palbociclib is a cyclin-dependent kinase 4 and 6 inhibitor approved for advanced breast cancer. In the adjuvant setting, the potential value of adding palbociclib to endocrine therapy for hormone receptor-positive breast cancer has not been confirmed.Patients and methods In the prospective, ...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!